Palisade Bio Execs to Present at Oppenheimer Healthcare Conference
Event summary
- Palisade Bio executives to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026.
- Presentation scheduled for 12:40 PM ET, with one-on-one investor meetings available.
- Palisade Bio's lead program, PALI-2108, achieved 100% clinical response in UC Phase 1b trial with no serious adverse events.
- Company advancing towards Phase 2 clinical study in UC and early studies in FSCD.
The big picture
Palisade Bio's presentation at the Oppenheimer conference comes as the company seeks to build momentum for its lead candidate, PALI-2108, following promising Phase 1b results. The targeted delivery mechanism of PALI-2108 aims to address tolerability issues common with systemic PDE4 inhibitors, positioning it as a potential differentiator in the treatment of inflammatory and fibrotic diseases. The upcoming Phase 2 trial will be critical in validating the clinical efficacy and safety profile of the drug.
What we're watching
- Clinical Development
- The pace at which Palisade Bio advances PALI-2108 through Phase 2 trials and potential expansion into other inflammatory bowel disease indications.
- Investor Sentiment
- How the market reacts to the presentation and one-on-one investor meetings, particularly regarding the Phase 2 trial design and maintenance of remission data.
- Competitive Positioning
- Whether Palisade Bio can differentiate PALI-2108's targeted delivery mechanism and tolerability profile in a crowded PDE4 inhibitor space.
Related topics